Patent: 8,828,668

Summary for Patent: 8,828,668

Title:	Markers for determination of patient responsiveness
Abstract:	Compositions and methods are provided for prognostic classification of inflammatory diseases, e.g. inflammatory demyelinating disease, patients into subtypes, which subtypes are informative of the patient\'s need for therapy and responsiveness to a therapy of interest. The patterns of cytokines provides for a signature pattern that can identify patients likely to benefit from therapeutic intervention as well as discriminate patients that have a high probability of responsiveness to a therapy from those that have a low probability of responsiveness. Assessment of this signature pattern thus allows improved methods of care. In one embodiment of the invention, the autoimmune disease is multiple sclerosis or neuromyelitis optica.
Inventor(s):	Axtell; Robert C. (Menlo Park, CA), Steinman; Lawrence (Stanford, CA), Han; May H. (Menlo Park, CA), de Jong; Brigit A. (Nijmegen, NL), Raman; Chander (Birmingham, AL), Walker; Michael (Carlsbad, CA), Shi; Jing (Carlsbad, CA)
Assignee:	The Board of Trustees of the Leland Stanford Junior University (Palo Alto, CA)
Application Number:	13/026,173
Patent Claims:	see list of patent claims

Details for Patent 8,828,668

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bayer Healthcare Pharmaceuticals Inc.	BETASERON	interferon beta-1b	For Injection	103471	07/23/1993		2039-03-29
Emd Serono, Inc.	REBIF	interferon beta-1a	Injection	103780	03/07/2002		2039-03-29
Emd Serono, Inc.	REBIF	interferon beta-1a	Injection	103780	12/17/2004		2039-03-29
Emd Serono, Inc.	REBIF	interferon beta-1a	Injection	103780	12/21/2012		2039-03-29
Janssen Biotech, Inc.	STELARA	ustekinumab	Injection	125261	09/25/2009		2039-03-29
Janssen Biotech, Inc.	STELARA	ustekinumab	Injection	125261	12/30/2009		2039-03-29
Novartis Pharmaceuticals Corporation	EXTAVIA	interferon beta-1b	For Injection	125290	08/14/2009		2039-03-29